Up to 30% off — ends 7 Aug

ONLY00h00m00s

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Chan Kim

CHA University School of Medicine

This profile is automatically generated from trusted academic sources.

Google Scholar

How do I reach out?

Meet Kite AI

Contact this professor

Research Interests

Internal Medicine

Targeted Therapy

Antibody Therapy

Cancer Biology

Tumor Immunology

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles16

Collaborators9

Seul-Gi Kim

Clinical Associate Professor

CHA Bundang Medical Center

Han Sang Kim

Associate Professor

Yonsei Cancer Center

Hong Jae Chon

Associate Professor

CHA Bundang Medical Center

Sung Hwan Lee

CHA University

Ilona Kryczek

University of Michigan

UNITED STATES

ilhwan kim

Associate Professor

Inje University Ilsan Paik Hospital

Sanghoon Jung

Assistant Professor

CHA Bundang Medical Center

Wooram Park

Assistant Professor

Sungkyunkwan University

Hannah Yang

University of Michigan

UNITED STATES

How do I reach out?

Meet Kite AI

Chan Kim

Assistant Professor

How do I reach out?

Contact this professor

Research Interests

Ask ApplyKite AI

Articles16

Reply to: Correspondence on ‘Concordance of ctDNA and tissue genomic profiling in advanced biliary tract cancer’

Impact of Coronavirus Disease 2019 on Unresectable Hepatocellular Carcinoma Treated with Atezolizumab/Bevacizumab

Itaconate transporter SLC13A3 impairs tumor immunity via endowing ferroptosis resistance

Oral reovirus reshapes the gut microbiome and enhances antitumor immunity in colon cancer

Concordance of ctDNA and tissue genomic profiling in advanced biliary tract cancer

Systemic Delivery of a STING Agonist-Loaded Positively Charged Liposome Selectively Targets Tumor Immune Microenvironment and Suppresses Tumor Angiogenesis.

High serum IL-6 correlates with reduced clinical benefit of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma.

ARID1A Mutation from Targeted NGS Predicts Primary Resistance to Gemcitabine and Cisplatin Chemotherapy in Advanced Biliary Tract Cancer

High Levels of Antidrug Antibodies Against Atezolizumab as a Predictive Marker for Clinical Outcomes in Patients With Hepatocellular Carcinoma—Reply

Atezolizumab plus bevacizumab in patients with child–Pugh B advanced hepatocellular carcinoma

Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial

PB101, a VEGF- and PlGF-targeting decoy protein, enhances antitumor immunity and suppresses tumor progression and metastasis

Association of High Levels of Antidrug Antibodies Against Atezolizumab With Clinical Outcomes and T-Cell Responses in Patients With Hepatocellular Carcinoma.

Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade.

Risk of Variceal Bleeding in Patients With Advanced Hepatocellular Carcinoma Receiving Atezolizumab/Bevacizumab

High endothelial venule is a surrogate biomarker for T-cell inflamed tumor microenvironment and prognosis in gastric cancer.

Collaborators9

Seul-Gi Kim

Han Sang Kim

Hong Jae Chon

Sung Hwan Lee

Ilona Kryczek

ilhwan kim

Sanghoon Jung

Wooram Park

Hannah Yang

How do I reach out?